150 related articles for article (PubMed ID: 36785917)
1. Cost-effectiveness of pancreas surveillance: The CDKN2A-p16-Leiden cohort.
Ibrahim IS; Vasen HFA; Wasser MNJM; Feshtali S; Bonsing BA; Morreau H; Inderson A; de Vos Tot Nederveen Cappel WH; van den Hout WB
United European Gastroenterol J; 2023 Mar; 11(2):163-170. PubMed ID: 36785917
[TBL] [Abstract][Full Text] [Related]
2. High Growth Rate of Pancreatic Ductal Adenocarcinoma in
Ibrahim IS; Wasser MN; Wu Y; Inderson A; de Vos Tot Nederveen Cappel WH; Morreau H; Hes FJ; Veenendaal RA; Putter H; Feshtali S; van Mil AM; Gruis NA; Tollenaar RA; Bergman W; Bonsing BA; Vasen HFA
Cancer Prev Res (Phila); 2018 Sep; 11(9):551-556. PubMed ID: 29991580
[No Abstract] [Full Text] [Related]
3. Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.
Ibrahim I; Sibinga Mulder BG; Bonsing B; Morreau H; Farina Sarasqueta A; Inderson A; Luelmo S; Feshtali S; Potjer TP; de Vos Tot Nederveen Cappel W; Wasser M; Vasen HFA
Eur J Hum Genet; 2018 Aug; 26(8):1227-1229. PubMed ID: 29769629
[TBL] [Abstract][Full Text] [Related]
4. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Cancer Surveillance in Carriers of a Germline
Klatte DCF; Boekestijn B; Wasser MNJM; Feshtali Shahbazi S; Ibrahim IS; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Dekker FW; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME
J Clin Oncol; 2022 Oct; 40(28):3267-3277. PubMed ID: 35658523
[TBL] [Abstract][Full Text] [Related]
6. Dilatation of the main pancreatic duct as first manifestation of small pancreatic ductal adenocarcinomas detected in a hereditary pancreatic cancer surveillance program.
Vasen HFA; Boekestijn B; Ibrahim IS; Inderson A; Bonsing BA; de Vos Tot Nederveen Cappel WH; Feshtali S; Wasser MN
HPB (Oxford); 2019 Oct; 21(10):1371-1375. PubMed ID: 30910317
[TBL] [Abstract][Full Text] [Related]
7. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer.
Ibrahim IS; Bonsing BA; Swijnenburg RJ; Welling L; Veenendaal RA; Wasser MN; Morreau H; Inderson A; Vasen HF
Fam Cancer; 2017 Jan; 16(1):111-115. PubMed ID: 27406244
[TBL] [Abstract][Full Text] [Related]
8. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic
Overbeek KA; Rodríguez-Girondo MD; Wagner A; van der Stoep N; van den Akker PC; Oosterwijk JC; van Os TA; van der Kolk LE; Vasen HFA; Hes FJ; Cahen DL; Bruno MJ; Potjer TP
J Med Genet; 2021 Apr; 58(4):264-269. PubMed ID: 32482799
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
10. Variation in precursor lesions of pancreatic cancer among high-risk groups.
Potjer TP; Schot I; Langer P; Heverhagen JT; Wasser MN; Slater EP; Klöppel G; Morreau HM; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bargello M; Gress TM; Vasen HF; Bartsch DK; ;
Clin Cancer Res; 2013 Jan; 19(2):442-9. PubMed ID: 23172884
[TBL] [Abstract][Full Text] [Related]
11. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis.
Klatte DCF; Boekestijn B; Onnekink AM; Dekker FW; van der Geest LG; Wasser MNJM; Feshtali S; Mieog JSD; Luelmo SAC; Morreau H; Potjer TP; Inderson A; Boonstra JJ; Vasen HFA; van Hooft JE; Bonsing BA; van Leerdam ME;
Gastroenterology; 2023 Jun; 164(7):1223-1231.e4. PubMed ID: 36889551
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Progression of Pancreatic Cystic Precursor Lesions Differ Between Groups at High Risk of Developing Pancreatic Cancer.
Konings IC; Harinck F; Poley JW; Aalfs CM; van Rens A; Krak NC; Wagner A; Nio CY; Sijmons RH; van Dullemen HM; Vleggaar FP; Ausems MG; Fockens P; van Hooft JE; Bruno MJ;
Pancreas; 2017 Jan; 46(1):28-34. PubMed ID: 27846136
[TBL] [Abstract][Full Text] [Related]
13. Distinction of Invasive Carcinoma Derived From Intraductal Papillary Mucinous Neoplasms From Concomitant Ductal Adenocarcinoma of the Pancreas Using Molecular Biomarkers.
Tamura K; Ohtsuka T; Date K; Fujimoto T; Matsunaga T; Kimura H; Watanabe Y; Miyazaki T; Ohuchida K; Takahata S; Ishigami K; Oda Y; Mizumoto K; Nakamura M; Tanaka M
Pancreas; 2016 Jul; 45(6):826-35. PubMed ID: 26646266
[TBL] [Abstract][Full Text] [Related]
14. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival.
Dbouk M; Katona BW; Brand RE; Chak A; Syngal S; Farrell JJ; Kastrinos F; Stoffel EM; Blackford AL; Rustgi AK; Dudley B; Lee LS; Chhoda A; Kwon R; Ginsberg GG; Klein AP; Kamel I; Hruban RH; He J; Shin EJ; Lennon AM; Canto MI; Goggins M
J Clin Oncol; 2022 Oct; 40(28):3257-3266. PubMed ID: 35704792
[TBL] [Abstract][Full Text] [Related]
15. Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers.
Ibrahim IS; Brückner C; Carrato A; Earl J; Inderson A; de Vos Tot Nederveen Cappel WH; Mintziras I; Matthäi E; Figiel J; Wasser M; Moreau H; Bonsing B; Slater EP; Bartsch DK; Vasen HF
United European Gastroenterol J; 2019 Jun; 7(5):682-688. PubMed ID: 31210946
[TBL] [Abstract][Full Text] [Related]
16. The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.
Kimura H; Klein AP; Hruban RH; Roberts NJ
Pancreas; 2021 Sep; 50(8):1123-1130. PubMed ID: 34714275
[TBL] [Abstract][Full Text] [Related]
17. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
18. Long-term yield of pancreatic cancer surveillance in high-risk individuals.
Overbeek KA; Levink IJM; Koopmann BDM; Harinck F; Konings ICAW; Ausems MGEM; Wagner A; Fockens P; van Eijck CH; Groot Koerkamp B; Busch ORC; Besselink MG; Bastiaansen BAJ; van Driel LMJW; Erler NS; Vleggaar FP; Poley JW; Cahen DL; van Hooft JE; Bruno MJ;
Gut; 2022 Jun; 71(6):1152-1160. PubMed ID: 33820756
[TBL] [Abstract][Full Text] [Related]
19. The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.
Luo Y; Tian L; Feng Y; Yi M; Chen X; Huang Q
Pathol Oncol Res; 2013 Jan; 19(1):35-40. PubMed ID: 22782330
[TBL] [Abstract][Full Text] [Related]
20. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
